LIVN vs SYK
LivaNova vs Stryker Corporation — AI-powered side-by-side comparison
VS
SYK
Stryker Corporation
70
Buy
| Metric | LIVN | SYK |
|---|
| AI Score |
70
|
70
|
| Price |
$82.25
|
$338.83
|
| P/E Ratio |
23.83×
|
34.86×
|
| ROE |
-20.2%
|
14.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
68.2%
|
65.2%
|
| Debt / Equity |
0.27×
|
0.62×
|
| Dividend Yield |
0.0%
|
1.0%
|
| RSI (14) |
60.6
|
49.4
|
| Beta |
0.872
|
0.771
|
| Expected Upside |
+0.8%
|
+10.4%
|
AI Committee View
Current Innellis committee reasoning for LIVN versus SYK.
The committee scores are tied.
LIVN and SYK both score 70/100.
LIVN Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- ROE of 15.4% shows genuine earnings power backing the valuation — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Risk/reward is unfavorable: 5.6% downside vs 0.8% upside.
SYK Committee View
75% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- News sentiment is positive (+0.33 across 31 articles, 14d) — News
Bear Case
- MACD histogram negative -- bearish momentum — Technical